Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Artivion ( (AORT) ) has provided an update.
On May 18, 2026, Artivion completed the acquisition of its long-time partner Endospan, exercising an option agreement first signed in 2019 and later amended. Through its Singapore subsidiary, Artivion paid a net upfront purchase price of about $131.3 million in cash, funded with a previously drawn $150 million term loan, and established escrow funds for indemnity and purchase-price adjustments.
The deal values Endospan at a base $175.0 million, with securityholders eligible for up to an additional $200.0 million in contingent consideration tied to the future performance of the NEXUS Aortic Arch System. The acquisition gives Artivion full ownership of the newly FDA-approved NEXUS platform and a pipeline of next-generation arch technologies, completing what the company calls a market-leading, three-pronged aortic arch portfolio and strengthening its competitive position in the global aortic arch solutions market.
The most recent analyst rating on (AORT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
The score is primarily supported by improving financial performance and a generally constructive earnings outlook (growth, margin expansion, and deleveraging). It is held back by very weak technical trend/momentum and a stretched valuation (very high P/E with no dividend yield), alongside near-term execution and acquisition-related cost/interest headwinds.
To see Spark’s full report on AORT stock, click here.
More about Artivion
Artivion, Inc. is a medical device company focused on cardiac and vascular surgery, particularly treatments for aortic diseases. Headquartered near Atlanta, it offers aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, and markets its products in more than 100 countries worldwide.
Privately held Endospan Ltd., based in Herzliya, Israel, specializes in endovascular repair of aortic arch disease, including aneurysms and dissections. Its NEXUS Aortic Arch System, which has CE-Mark in Europe and FDA PMA approval in April 2026, targets an underserved patient group that previously relied largely on open-chest surgery.
Average Trading Volume: 545,679
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.11B
For detailed information about AORT stock, go to TipRanks’ Stock Analysis page.